Biocompatibles Refocusing R&D Efforts On Cardiovascular Drug Delivery
This article was originally published in The Gray Sheet
Executive Summary
Biocompatibles International will spend about $4.5 mil. annually on cardiovascular drug delivery R&D, as the company focuses its product development activities on a newly formed drug delivery division, the firm noted in a July 6 quarterly update.